Table 1: Current Guideline Recommendations for Intravenous Iron in Heart Failure.

Body	Year	Recommendation	Class/Level of Evidence
European Society of Cardiology[19]	2016	IV iron (ferrous carboxymaltose) should be considered in symptomatic HFrEF and ID (absolute or functional)	IIa/A
American College of Cardiology/American Heart Association[50]	2017	IV iron might be reasonable in patients with NYHA class II-III and ID (absolute or functional)	IIb/B
Scottish Intercollegiate Guidelines Network[51]	2016	Consider IV iron in those with NYHA class III and LVEF ≤45 % or NYHA class II and LVEF ≤40 %, ID and haemoglobin 9.5–13.5 g/dl	Recommended/1++ (high-quality metaanalyses, systematic reviews of RCTs, or RCTs with a very low risk of bias)

HFrEF = heart failure with reduced ejection fraction; ID = iron deficiency; IV = intravenous; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; RCT = randomised controlled trial. The National Institute for Health and Care Excellence updated guideline for HF is due to be published in 2018; there is no mention of iron deficiency in the most recent guideline (2010).^[52]